Recently, abemaciclib and other CDK4/6 inhibitors have been shown to enhance antitumor immunity in preclinical models by overcoming two central mechanisms of tumor immune evasion [91,92,93]: first, CDK4/6 inhibitors activate the tumor cell expression of endogenous retroviral elements, thus increasing intracellular levels of double-stranded RNA. The gene discussed is CDK4; the disease is neoplasm.